These findings suggest that EVs transfer in NPC patients plays a novel non‐redundant regulatory role in the malignant transformation of NPC and reveal the potential of EGFR‐rich EVs and ROS as novel therapeutic targets for the treatment of NPC. Here, EGFR is linked to nasopharyngeal carcinoma.